Business
Why the Mesoblast (ASX:MSB) share price is sinking 11% lower
The Mesoblast limited (ASX: MSB) share price has come under pressure on Tuesday after the release of an announcement.
At the time of writing the allogeneic cellular medicines developer’s shares are down 11% to $4.03.
What did Mesoblast announce?
This morning Mesoblast announced the top-line results from the landmark DREAM-HF Phase 3 randomised controlled trial of its allogeneic cell therapy rexlemestrocel-L (REVASCOR) in 537 patients with advanced chronic heart failure.
According to the release, after a 30-month follow-up, patients with advanced chronic heart failure who received a single endomyocardial treatment with rexlemestrocel-L on top of maximal therapies had a 60% reduction in the incidence of heart attacks or strokes and…
-
Noosa News17 hours agoMuster Dogs favourite Frank Finger makes final on-screen appearance with kelpie Annie in portrait show
-
General7 hours agoGoldfields man in coma after allegedly smashing head into ambulance windscreen
-
Noosa News17 hours agoWhy commuters are less likely to see familiar strangers on the bus, train or CityCat and why that makes us feel less safe
-
General24 hours agoBen Stokes questions England’s ability to handle Ashes pressure as Brendon McCullum warns of ‘glass jaw’